Because almost 40% of ER+ breast cancers harbor PIK3CA mutations [30,111], combination therapies using alpelisib or taselisib with endocrine therapies have been extensively tested in clinical trials [112,113]. This evidence concerns the gene PIK3CA and breast carcinoma.